CTO Salvatore Privitera Sells 8,404 Shares, Impacting AtriCure’s Investor Sentiment

Insider Selling Hot‑Spot: AtriCure’s CTO Triggers a Big Sale

On November 4, 2026 the Chief Technical Officer (CTO) of AtriCure, Salvatore Privitera, executed a sizable sale of 8,404 shares at $65.00 per share under a 10(b)(5)(1) trading plan. The transaction closed at a price only marginally below the market close of $65.53, reducing Privitera’s holdings to 134,341 shares—just under 4 % of the company’s outstanding shares.

Impact on Shareholder Value

Privitera’s rapid turnover contrasts sharply with the company’s robust earnings report released on the same day. AtriCure posted a 15 % year‑over‑year revenue lift to $154 million and an adjusted EBITDA increase to $26.8 million. The results fueled a bullish annual growth projection of 14 % and a 91 % increase in market capitalization from the prior year.

While the 10(b)(5)(1) plan mitigates market impact—allowing a pre‑planned exit rather than a panic sell—the frequency of the CTO’s sales raises questions about his assessment of the company’s valuation trajectory. Selling at a price only slightly below the prevailing market can signal a lack of confidence in near‑term upside or a need for liquidity.

Insider Activity in Context

Between September 1 and November 4, Privitera completed six large sales that collectively represent roughly 22 % of his post‑trade holdings. This pace is markedly higher than the company‑wide insider selling rate, which averaged about 5 % of shares in the same period. Other executives—CEO Michael Carrel and Chief Scientific Officer Vinayak Doraiswamy—have also been active, but their trades are spread over longer intervals and involve smaller totals. The concentrated activity by the CTO suggests a strategic decision to rebalance his portfolio, potentially in anticipation of a future upside that is not yet reflected in the public markets.

Privitera’s Trading Profile

Privitera’s transaction history shows a consistent use of the 10(b)(5)(1) plan, with sales occurring every few weeks since March. He has never been a significant buyer; his only purchases were a modest 636‑share buy in late June and a 30,390‑share acquisition in March. His sales typically average $60–65 per share, slightly below the 2026 average share price of $65.53, implying he is selling at a discount to the prevailing market. This disciplined, plan‑based approach indicates a long‑term view but also a willingness to liquidate positions when the market price lags his valuation models.

Forward Guidance and Market Sentiment

AtriCure’s guidance for 2027 remains upbeat, with projected revenues of $606–$610 million and EBITDA of $91–$94 million. However, the heavy insider selling may temper investor enthusiasm and could contribute to short‑term volatility. Analysts should monitor whether Privitera’s trend continues and whether other insiders follow suit. If insider outflows persist, it may be prudent to reassess AtriCure’s valuation multiples—currently a lofty 285.91 P/E—and the sustainability of its growth narrative.

Investors will do well to watch AtriCure’s earnings calls and subsequent filings for clues on whether the CTO’s selling signals a strategic shift or simply a routine portfolio rebalancing.